(lp0
S'Trading Summary: Watching Shares of Endocyte, Inc.  Benton Bulletin - 11 hours ago Endocyte, Inc.  has a current Piotroski F-Score of 2. The mission of the F-Score is to help spot companies with strengthening balance sheets, and to weed out poor performers.'
p1
aS'Endocyte  Up 3.5% Since Earnings Report: Can It Continue? Yahoo Finance - Apr 10, 2017 It has been about a month since the last earnings report for Endocyte, Inc. ECYT. Shares have added about 3.5% in that time frame, outperforming the market.'
p2
aS"Endocyte's NSCLC Drug: Any Residual Value? Seeking Alpha - Mar 24, 2017 Endycyte  develops small molecule drug conjugates and companion diagnostics for the treatment of cancer and inflammatory diseases."
p3
aS'Endocyte Appoints Michael T. Andriole as Chief Financial Officer GlobeNewswire  - Feb 21, 2017 WEST LAFAYETTE, Ind., Feb. 21, 2017  -- Endocyte, Inc. , a leader in developing targeted small molecule drug conjugates  and companion imaging agents for personalized therapy, today announced that&nbsp;...'
p4
aS'Inside the Numbers on Shares of Endocyte, Inc.  BVN - 9 hours ago Investors may be checking on some financial ratios for Endocyte, Inc. . Currently, the company has a Gross Margin  ratio of -0.191102.'
p5
aS'Endocyte: A Must Buy While Wall Street Goes Insane Seeking Alpha - Jan 21, 2016 During past few months, while the whole biotech sector has been melting down, Endocyte  has been no exception.'
p6
aS'Endocyte: Small Company, Small Valuation, Full Pipeline Seeking Alpha  - Jan 29, 2015 Endocyte, Inc.  is a biopharmaceutical company based out of West Lafayette, IN. The company is currently developing therapies that target both cancers and inflammatory diseases.'
p7
aS'Endocyte to Present at the IASLC 17th World Conference on Lung Cancer GlobeNewswire  - Dec 1, 2016 WEST LAFAYETTE, Ind., Dec. 01, 2016  -- Endocyte, Inc. , a leader in developing targeted small molecule drug conjugates  and companion imaging agents for personalized therapy, today announced that data&nbsp;...'
p8
aS'Endocyte Announces Presentations at American Association for Cancer Research ... GlobeNewswire  - Mar 27, 2017 WEST LAFAYETTE, Ind., March 27, 2017  -- Endocyte, Inc. , a leader in developing targeted small molecule drug conjugates  and companion imaging agents for personalized therapy, today announced that&nbsp;...35 hedge funds sold their entire positions in Endocyte, Inc.  - Post AnalystEndocyte, Inc.  eight posters will be presented by Endocyte ... - Benchmark Monitor'
p9
aS'Endocyte, Inc.  loses confidence of 9 hedge fund managers Post Analyst - 21 hours ago Endocyte, Inc.  reached 13.13% versus a 1-year low price of $1.98. The stock was last seen -0.88% lower, reaching at $2.24 on Apr. 13, 2017.Endocyte, Inc.  Reviewed By Analysts - The De Soto Edge'
p10
a.